Effectiveness of the 10 cm
Alzheimer’s disease
Cognitive function
Rivastigmine patch
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
27
05
2021
accepted:
11
08
2021
pubmed:
11
9
2021
medline:
12
10
2021
entrez:
10
9
2021
Statut:
ppublish
Résumé
The current study aimed to provide data on the effectiveness of the 10 cm This was a 48-week, single-arm, open-label, observational, and post-marketing study conducted across seven centers in Taiwan between May 5, 2016 and July 10, 2017. Eligible patients (aged 55-95 years) treated with the 10 cm Of the 285 eligible patients [full analysis set (FAS)], 216 (75.8%) completed the study protocol while 180 (63.2%) persisted on the 10 cm The use of the 10 cm
Identifiants
pubmed: 34506009
doi: 10.1007/s12325-021-01893-6
pii: 10.1007/s12325-021-01893-6
pmc: PMC8478746
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Rivastigmine
PKI06M3IW0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5286-5301Informations de copyright
© 2021. The Author(s).
Références
World Alzheimer Report 2019. Alzheimer’s disease international: attitudes to dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf . Accessed 16 Dec 2019.
Wang WF, Chiu PY, Lin YT, Hu CJ, Fuh JL, Yang YH. Registration of Alzheimer’s disease in Taiwan: patient and informant. Am J Alzheimers Dis Other Demen. 2014;29:18–22.
doi: 10.1177/1533317513504818
Fan LY, Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, et al. Marital status, lifestyle and dementia: a nationwide survey in Taiwan. PLoS ONE. 2015;10: e0139154.
doi: 10.1371/journal.pone.0139154
Chang CC, Peng GS, Lai TJ, Li CH, Liu CK. A 48-week, multicenter, open-label, observational study evaluating oral rivastigmine in patients with mild-to-moderate Alzheimer’s disease in Taiwan. Adv Ther. 2019;36:1455–64.
doi: 10.1007/s12325-019-00939-0
Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-22.
doi: 10.1212/01.wnl.0000281847.17519.e0
Sadowsky CH, Micca JL, Grossberg GT, Velting DM. Rivastigmine from capsules to patch: Therapeutic advances in the management of Alzheimer’s disease and Parkinson’s disease dementia. Prim Care Companion CNS Disord. 2014. https://doi.org/10.4088/PCC.14r01654 .
doi: 10.4088/PCC.14r01654
pubmed: 25667813
pmcid: 4321018
Gauthier S, Juby A, Dalziel W, Réhel B. Schecter R and on behalf of the EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE). Curr Med Res Opin. 2010;26:1149–60.
doi: 10.1185/03007991003688888
Sabbagh MN, Malek-Ahmadia M, Kataria R, Beldena CM, Connor DJ, Pearson C, et al. The Alzheimer’s questionnaire: a proof of concept study for a new informant-based dementia assessment. J Alzheimers Dis. 2010;22:1015–21.
doi: 10.3233/JAD-2010-101185
Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6:45–58.
doi: 10.1017/S1041610294001602
Yang YH, Wu MN, Chou PS, Su HC, Lin SH, Sung PS. Longitudinal neuropsychological outcome in Taiwanese Alzheimer’s disease patients treated with medication. Curr Alzheimer Res. 2018;15:474–81.
doi: 10.2174/1567205014666171010112518
Geldmacher DS. Treatment guidelines for Alzheimer’s disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007;9:113–21.
doi: 10.4088/PCC.v09n0205
Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23:2705–13.
doi: 10.1185/030079907X233403
Chang CJ, Chou TC, Chang CC, Chen TF, Hu CJ, Fuh JL, et al. Persistence and adherence to rivastigmine in patients with dementia: results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan. Alzheimers Dement (N Y). 2019;5:46–51.
doi: 10.1016/j.trci.2018.06.013
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
doi: 10.1016/j.jalz.2011.03.005
Chou MC, Chen CH, Liu CK, Chen SH, Wu SJ, Yang YH. Concentrations of rivastigmine and NAP 226–90 and the cognitive response in Taiwanese Alzheimer’s disease patients. J Alzheimers Dis. 2012;31:857–64.
doi: 10.3233/JAD-2012-120109
Winbald B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease––rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456–67.
doi: 10.1002/gps.1788
Kurz A, Farlow M, Lefe’vre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int J Clin Pract. 2009;63:799–805.
doi: 10.1111/j.1742-1241.2009.02052.x
Chou PS, Jhang KM, Huang LC, Wang WF, Yang YH. Skinfold thickness for rivastigmine patch application in Alzheimer’s disease. Psychopharmacology. 2019;236:1255–60.
doi: 10.1007/s00213-018-5135-x
Aevarsson O, Skoog I. A longitudinal population study of the mini-mental state examination in the very old: relation to dementia and education. Dement Geriatr Cogn Disord. 2000;11:166–75.
doi: 10.1159/000017231
Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, et al. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Curr Med Res Opin. 2013;29:989–1000.
doi: 10.1185/03007995.2013.802230
Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand. 2009;119:180–5.
doi: 10.1111/j.1600-0404.2008.01086.x
Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci. 2015;36:457–63.
doi: 10.1007/s10072-014-2002-3
Lai TH, Wang WF, Yip BS, Yang YW, Peng GS, Tsai SJ, et al. Real-world evaluation of compliance and preference in Alzheimer’s disease treatment: an observational study in Taiwan. Patient Prefer Adherence. 2016;10:383–90.
pubmed: 27099476
pmcid: 4821393
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, DalBianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318:633–8.
doi: 10.1136/bmj.318.7184.633
Articus K, Baier M, Tracik F, Kühn F, Preuß UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease. Int J Clin Pract. 2011;65:790–6.
doi: 10.1111/j.1742-1241.2011.02713.x
Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707–14.
doi: 10.1185/030079903125002450
Exelon patch®. US prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf . Accessed 30 Oct 2019.
Exelon® for oral use. US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020823s036,021025s024lbl.pdf . Accessed 30 Aug 2021.
Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999;36:153–62.
doi: 10.1016/S0020-7489(99)00003-6
Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract. 2006;60:110–8.
doi: 10.1111/j.1368-5031.2005.00769.x
Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of Rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18:129–38.
doi: 10.1185/030079902125000471
Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2009;24:267–75.
doi: 10.1177/1533317509333037
Sadowsky CH, Dengiz A, Meng X, Olin JT. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer’s disease: 20-week extension phase results. Prim Care Companion J Clin Psychiatry. 2010;12:PCC.09m00852.
pubmed: 21274364
pmcid: 3025991